title: Effective application of ET-Kyoto solution for clinical lung transplantation.
abstract: The shortage of lung donors and ischemia-reperfusion injury following transplantation have been grave problems in lung transplantation (LTx). One of the most important strategies to solve these problems is the development of effective and highly reliable methods for lung preservation. Therefore, we developed a new organ preservation solution, namely, the extracellular-type trehalose-containing Kyoto (ET-Kyoto) solution. Here we report the first experience of clinical application of ET-Kyoto solution for cadaveric LTx. The recipient was a 38-year-old man with pulmonary emphysema. The donor was a 51-year-old male current smoker with a smoking history of 62 pack-years. The ventilated donor's PaO(2) was 340 Torr (FiO(2) = 1.0). The pulmonary vasculature was flushed with ET-Kyoto solution supplemented with nitroglycerine and dibutyryl cAMP. The recipient underwent bilateral sequential LTx on cardiopulmonary bypass. The ischemic time was 544 and 613 minutes for the left and right lung, respectively. PaO(2) (FiO(2) = 1.0) was 385 Torr immediately after reperfusion. The donor lung was so large that bilateral partial resections were performed at 413 minutes (right) and 348 minutes (left) after reperfusion. On histopathologic examination of the resected transplanted lungs the structure was almost normal. Postoperatively, PaO(2) (FiO(2) = 1.0) was over 400 Torr with or maximum of 526 Torr. The clinical course was almost uneventful. In conclusion, ET-Kyoto solution may be safely applied in clinical cadaveric LTx with extended donor lungs and relatively long ischemic times. Functional and histopathological efficiency of ET-Kyoto solution was confirmed. Longer preservation times with preserved quality using ET-Kyoto solution would increase the donor pool and enable semielective LTx.
authors.affiliation: Department of Thoracic Surgery, Kyoto University, 54 Shogoin, Sakyo-ku, Kyoto 606-8507, Japan.
authors.forename: F
authors.initials: F
authors.lastname: Chen
authors.forename: T
authors.initials: T
authors.lastname: Fukuse
authors.forename: S
authors.initials: S
authors.lastname: Hasegawa
authors.forename: T
authors.initials: T
authors.lastname: Bando
authors.forename: N
authors.initials: N
authors.lastname: Hanaoka
authors.forename: M
authors.initials: M
authors.lastname: Kawashima
authors.forename: H
authors.initials: H
authors.lastname: Sakai
authors.forename: H
authors.initials: H
authors.lastname: Hamakawa
authors.forename: T
authors.initials: T
authors.lastname: Fujinaga
authors.forename: T
authors.initials: T
authors.lastname: Nakamura
authors.forename: H
authors.initials: H
authors.lastname: Wada
mesh_terms: D000328:Adult; D004646:Emphysema / Q000601:surgery*; D005942:Gluconates; D006801:Humans; D006895:Hydroxyethyl Starch Derivatives; D016040:Lung Transplantation / Q000502:physiology*; D008297:Male; D008875:Middle Aged; D009926:Organ Preservation / Q000379:methods; D019188:Organ Preservation Solutions; D010710:Phosphates; D012907:Smoking; D014019:Tissue Donors; D014199:Trehalose
chemical_list: C087059:ET-Kyoto solution; D005942:Gluconates; D006895:Hydroxyethyl Starch Derivatives; D019188:Organ Preservation Solutions; D010710:Phosphates; D014199:Trehalose